News and Trends 31 Jan 2020
AI-Designed Drug Enters Phase I to Treat OCD
A drug designed by the UK firm Exscientia using AI-powered software has entered into a phase I clinical trial for the treatment of obsessive-compulsive disorder, commonly known as OCD. The clinical development of the drug will be carried out by Sumitomo Dainippon Pharma, Exscientia’s Japanese collaborator. The drug took just 12 months to get to […]